ITIL-306 for Non-small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-small Cell Lung Cancer+2 MoreITIL-306 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cell therapy for adults with solid tumors that have progressed after standard therapy. The therapy is derived from the patient's own tumor-infiltrating immune cells and is designed to increase activity against the tumor when it encounters a specific molecule on the tumor.

Eligible Conditions
  • Non-small Cell Lung Cancer
  • Ovarian Cancer
  • Kidney Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
PF-07284890
1
PF-07248144
1
Antineoplastic Immune Cell

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Up to 60 months

Up to 24 months
Therapeutic procedure
Up to 60 months
Duration of response (DOR)
Objective response rate (ORR)
Overall Survival (OS)
Progression-free survival (PFS)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
PF-07284890
1
PF-07248144
1
Antineoplastic Immune Cell

Trial Design

2 Treatment Groups

Phase 1b: Expansion
1 of 2
Phase 1a: Dose Escalation
1 of 2

Experimental Treatment

51 Total Participants · 2 Treatment Groups

Primary Treatment: ITIL-306 · No Placebo Group · Phase 1

Phase 1b: Expansion
Biological
Experimental Group · 1 Intervention: ITIL-306 · Intervention Types: Biological
Phase 1a: Dose Escalation
Biological
Experimental Group · 1 Intervention: ITIL-306 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 60 months

Who is running the clinical trial?

Instil BioLead Sponsor
2 Previous Clinical Trials
130 Total Patients Enrolled
1 Trials studying Non-small Cell Lung Cancer
Instil Study DirectorStudy DirectorInstil Bio, Inc.
2 Previous Clinical Trials
130 Total Patients Enrolled
1 Trials studying Non-small Cell Lung Cancer

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Cohort 2: Squamous-cell carcinoma or adenocarcinoma of the lung.
You have histologically documented advanced (metastatic and/or unresectable) disease as appropriate per cohort.
You have had a complete tumor resection for TIL harvest
You have clear cell or papillary RCC.

Who else is applying?

What state do they live in?
Texas100.0%
What site did they apply to?
Washington University School of Medicine100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top